#1 Clinical Trials Search in Europe

Mitazalimab

A new clinical trial is investigating the use of Mitazalimab, a CD40 antibody, in combination with Irreversible Electroporation (IRE) for patients with locally advanced pancreatic cancer. This innovative approach aims to enhance the immune system’s response against cancer cells while minimizing side effects. The study focuses on the safety and effectiveness of this treatment combination, offering hope for improved outcomes in pancreatic cancer patients.

Table of Contents

What is Mitazalimab?

Mitazalimab is a type of medication known as a CD40 antibody. It is currently being studied as a potential treatment for locally advanced pancreatic cancer[1]. Locally advanced pancreatic cancer refers to tumors that have not spread to distant parts of the body but cannot be surgically removed due to their size or location.

How Mitazalimab Works

Mitazalimab works by targeting and stimulating a specific receptor in the immune system called CD40. This receptor plays a crucial role in helping the immune system recognize and fight cancer cells. By activating CD40, mitazalimab aims to enhance the body’s natural ability to combat pancreatic cancer[1].

Treatment Approach: Combining Mitazalimab with IRE

In the current clinical trial, mitazalimab is being used in combination with a procedure called Irreversible Electroporation (IRE). IRE is a form of non-thermal ablation, which means it destroys cancer tissue without using heat. Here’s how the combined treatment works:

  1. IRE Procedure: First, doctors perform IRE on the pancreatic tumor. This procedure uses short, strong electric pulses to destroy cancer cells and create inflammation in the tumor area[1].
  2. Mitazalimab Injection: Five minutes after completing IRE, mitazalimab is injected directly into the center of the treated tumor area[1].
  3. Immune Response: The combination of IRE and mitazalimab is designed to stimulate a strong immune response against the cancer cells[1].

Current Clinical Trial

Mitazalimab is currently being studied in a Phase I clinical trial for patients with locally advanced pancreatic cancer. The trial aims to determine:

  • The safety and tolerability of intratumoral (injected directly into the tumor) mitazalimab when combined with IRE[1].
  • The most appropriate dose of mitazalimab for future studies[1].
  • Preliminary evidence of the treatment’s effectiveness[1].

Potential Benefits

The researchers hope that this new approach of combining mitazalimab with IRE may offer several potential benefits:

  • Enhanced Immune Effects: The combination may boost the immune-stimulating effects of IRE, potentially leading to a stronger anti-cancer response[1].
  • Reduced Risk of Recurrence: By enhancing the immune response, the treatment may help lower the chances of cancer coming back[1].
  • Fewer Side Effects: Injecting mitazalimab directly into the tumor (instead of into the bloodstream) may reduce system-wide side effects while potentially increasing its effectiveness[1].

Safety and Side Effects

As this is a Phase I clinical trial, one of the main goals is to assess the safety and tolerability of the treatment. The researchers will be closely monitoring for any side effects or adverse events that may occur. Some potential side effects that will be watched for include:

  • Cytokine Release Syndrome: A condition where the immune system becomes overly activated, potentially causing symptoms like fever, nausea, and fatigue[1].
  • Other immune-related side effects that may occur with immunotherapy treatments.

It’s important to note that as this is an early-stage clinical trial, the full range of potential side effects is not yet known. Patients participating in the trial will be closely monitored for any unexpected reactions[1].

Aspect Details
Study Type Phase I clinical trial
Treatment Intratumoral Mitazalimab (CD40 antibody) with Irreversible Electroporation (IRE)
Condition Locally advanced pancreatic cancer
Primary Outcome Safety and tolerability
Secondary Outcomes Progression-free survival, Overall survival, Systemic immune effects
Administration Method Intratumoral injection following IRE procedure
Study Design Dose escalation (Phase IA) followed by expansion cohort (Phase IB)

FAQ

  • What is Mitazalimab and how does it work? Mitazalimab is a type of antibody that targets the CD40 receptor in the immune system. It helps stimulate the immune system to recognize and fight cancer cells more effectively. In this trial, it's being used to potentially boost the immune effects of Irreversible Electroporation (IRE) treatment in pancreatic cancer.
  • What is Irreversible Electroporation (IRE)? IRE is a non-thermal ablation technique used to destroy cancer cells in locally advanced pancreatic tumors. It uses electrical pulses to create tiny holes in cancer cell membranes, leading to cell death. This method may also help release tumor antigens, which can stimulate an immune response against the cancer.
  • How is Mitazalimab administered in this trial? In this trial, Mitazalimab is injected directly into the tumor (intratumorally) shortly after the IRE procedure. This local delivery method is being tested to potentially increase effectiveness and reduce systemic side effects compared to traditional intravenous administration.
  • Who is eligible for this clinical trial? This trial is designed for patients with locally advanced pancreatic cancer. These are tumors that have not spread to other parts of the body but cannot be surgically removed. Specific eligibility criteria would be determined by the study investigators.
  • What are the main goals of this clinical trial? The primary goal is to assess the safety and tolerability of combining Mitazalimab with IRE. Secondary goals include measuring progression-free survival, overall survival, and evaluating the treatment's effects on the immune system. The researchers hope this combination will enhance the immune response against the cancer and reduce the risk of recurrence.

Ongoing Clinical Trials on Mitazalimab

  • Study of Mitazalimab Injection Treatment for Patients with High-Risk Oral Potentially Malignant Disorders

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Safety and Effectiveness of Mitazalimab with Chemotherapy for Patients with Metastatic Pancreatic Cancer

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Spain

Glossary

  • CD40: A protein found on certain immune cells that plays a crucial role in activating the immune system's response against threats, including cancer cells.
  • Agonistic antibody: A type of antibody that binds to a receptor and activates it, stimulating a biological response. In this case, Mitazalimab is an agonistic antibody that activates the CD40 receptor.
  • Intratumoral: Refers to the administration of a treatment directly into a tumor, as opposed to delivering it through the bloodstream.
  • Locally advanced pancreatic cancer: A stage of pancreatic cancer where the tumor has grown beyond the pancreas and involves nearby blood vessels, but has not spread to distant parts of the body.
  • Irreversible Electroporation (IRE): A non-thermal ablation technique that uses short electrical pulses to create permanent pores in cancer cell membranes, leading to cell death.
  • Antigen: Any substance that causes the immune system to produce antibodies against it. In cancer, tumor antigens can potentially stimulate an immune response.
  • Dose-limiting toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dosage or require a reduction in dose.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Overall survival (OS): The length of time from the start of treatment that patients diagnosed with the disease are still alive.
  • Neoantigen: A type of antigen that is created by mutations in tumor cells and can be recognized by the immune system as foreign.

References

  1. https://clinicaltrials.gov/study/NCT06205849